Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 11, 2021 09:00 ET | Source: Longeveron

Longeveron to Release First Quarter 2021 Financial Results and Hold Conference Call on May 14, 2021

MIAMI, May 11, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and...
May 05, 2021 09:00 ET | Source: Longeveron

Longeveron Invited to Present at the Benzinga Global Small Cap Conference

Longeveron recently announced positive results from a Phase 1 study of Lomecel-B in Alzheimer's disease, and the completion of two Phase 2 clinical trials evaluating the safety and efficacy of...
April 27, 2021 09:00 ET | Source: Longeveron

Longeveron Selected to Present at the 2021 World Stem Cell Summit

MIAMI, April 27, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related...
April 15, 2021 08:30 ET | Source: Longeveron

Longeveron Announces Successful Completion of Phase I/II Clinical Study of Lomecel-B Infusion in Aging Frailty Subjects to Improve Immune Response Following Influenza Vaccination

Study intended to evaluate safety, and potential immunomodulatory effect of Lomecel-B on aging-associated decline in antibody response to vaccines in vulnerable population. Trial funded in part by a...
April 13, 2021 08:30 ET | Source: Longeveron

Longeveron Announces Positive Results of Phase I Clinical Study of Lomecel-B Cell Therapy for Alzheimer’s Disease

Study meets primary safety endpoint; positive secondary efficacy assessments support potential benefit from Lomecel-B Decline in cognitive function slower in patients who received low-dose Lomecel-B...
March 30, 2021 07:00 ET | Source: Longeveron

Longeveron Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results

MIAMI, March 30, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related...
March 26, 2021 09:00 ET | Source: Longeveron

Longeveron Schedules 2020 Fiscal Year End Business Update Conference Call

MIAMI, March 26, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related...
March 15, 2021 16:30 ET | Source: Longeveron

Longeveron Inc. Announces Partial Exercise of Over-Allotment Option in Initial Public Offering

MIAMI, March 15, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or the "Company"), a clinical stage biotechnology company developing cellular therapies for chronic...
March 11, 2021 09:00 ET | Source: Longeveron

Longeveron’s Lomecel-B™ Approved by FDA for Compassionate Use for the Treatment of Child with Hypoplastic Left Heart Syndrome (HLHS)

MIAMI, March 11, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related...
March 10, 2021 08:30 ET | Source: Longeveron

Longeveron and University of Miami Expand Exclusive License Agreement, and Enter into CRADA To Facilitate Future Collaborations

MIAMI, March 10, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related...